Texas Permanent School Fund Boosts Holdings in LivaNova PLC (LIVN)

Texas Permanent School Fund boosted its position in shares of LivaNova PLC (NASDAQ:LIVN) by 8.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,574 shares of the company’s stock after buying an additional 2,440 shares during the quarter. Texas Permanent School Fund owned approximately 0.06% of LivaNova worth $3,790,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LIVN. grace capital acquired a new position in LivaNova during the 2nd quarter worth $100,000. Envestnet Asset Management Inc. lifted its holdings in LivaNova by 1,054.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock worth $166,000 after buying an additional 1,518 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in LivaNova during the 1st quarter worth $174,000. Cerebellum GP LLC acquired a new position in LivaNova during the 3rd quarter worth $191,000. Finally, Gideon Capital Advisors Inc. acquired a new position in LivaNova during the 2nd quarter worth $218,000. 87.18% of the stock is currently owned by hedge funds and other institutional investors.

LIVN opened at $111.24 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.51 and a quick ratio of 1.08. LivaNova PLC has a 12 month low of $72.30 and a 12 month high of $131.54. The firm has a market capitalization of $5.56 billion, a P/E ratio of 33.61, a PEG ratio of 3.35 and a beta of 0.95.



LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 1st. The company reported $0.96 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The business had revenue of $287.50 million during the quarter, compared to analysts’ expectations of $278.08 million. During the same quarter in the prior year, the company earned $0.93 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts forecast that LivaNova PLC will post 3.18 earnings per share for the current fiscal year.

In related news, insider Douglas John Manko sold 2,058 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $121.61, for a total value of $250,273.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $112.83, for a total transaction of $169,245.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,058 shares of company stock valued at $963,033. 0.41% of the stock is owned by corporate insiders.

LIVN has been the subject of several recent research reports. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 18th. Stifel Nicolaus upped their target price on shares of LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, September 17th. Needham & Company LLC reiterated a “buy” rating and set a $135.00 target price (up previously from $128.00) on shares of LivaNova in a research report on Wednesday, August 1st. Jefferies Financial Group upped their target price on shares of LivaNova to $150.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research cut shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, September 20th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. LivaNova presently has an average rating of “Buy” and a consensus target price of $113.33.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Featured Article: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply